Log in

Yield10 Bioscience Stock Price, News & Analysis (NASDAQ:YTEN)

$0.62
-0.03 (-4.62 %)
(As of 10/22/2019 08:00 AM ET)
Today's Range
$0.61
Now: $0.62
$0.65
50-Day Range
$0.51
MA: $0.64
$0.79
52-Week Range
$0.50
Now: $0.62
$1.77
Volume15,600 shs
Average Volume88,215 shs
Market Capitalization$7.76 million
P/E RatioN/A
Dividend YieldN/A
Beta3.15
Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. Read More…

Industry, Sector and Symbol

Industry Miscellaneous plastics products
Sub-IndustryN/A
SectorConsumer Staples
Current SymbolNASDAQ:YTEN
CUSIPN/A
Phone617-583-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$560,000.00
Book Value$0.57 per share

Profitability

Net Income$-9,170,000.00
Net Margins-1,320.21%

Miscellaneous

Employees22
Market Cap$7.76 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive YTEN News and Ratings via Email

Sign-up to receive the latest news and ratings for YTEN and its competitors with MarketBeat's FREE daily newsletter.


Yield10 Bioscience (NASDAQ:YTEN) Frequently Asked Questions

What is Yield10 Bioscience's stock symbol?

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

When did Yield10 Bioscience's stock split? How did Yield10 Bioscience's stock split work?

Yield10 Bioscience's stock reverse split on the morning of Tuesday, May 30th 2017. The 1-10 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 10 shares after the split.

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience Inc (NASDAQ:YTEN) released its quarterly earnings data on Monday, August, 12th. The specialty chemicals company reported ($0.15) EPS for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.06. The specialty chemicals company had revenue of $0.32 million for the quarter. Yield10 Bioscience had a negative net margin of 1,320.21% and a negative return on equity of 145.61%. View Yield10 Bioscience's Earnings History.

When is Yield10 Bioscience's next earnings date?

Yield10 Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Yield10 Bioscience.

What price target have analysts set for YTEN?

3 analysts have issued 1 year price targets for Yield10 Bioscience's stock. Their predictions range from $2.00 to $5.00. On average, they anticipate Yield10 Bioscience's stock price to reach $3.33 in the next year. This suggests a possible upside of 437.6% from the stock's current price. View Analyst Price Targets for Yield10 Bioscience.

What is the consensus analysts' recommendation for Yield10 Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Yield10 Bioscience.

What are Wall Street analysts saying about Yield10 Bioscience stock?

Here are some recent quotes from research analysts about Yield10 Bioscience stock:
  • 1. According to Zacks Investment Research, "Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. " (10/19/2019)
  • 2. National Securities analysts commented, " Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR - €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
     A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
     No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
     Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component." (8/20/2019)
  • 3. Aegis analysts commented, "We expect a repeat on 2018 field trials with positive results, especially within C3003 in canola and camelina which should help YTEN pull forward collaboration with the company’s large AG major partners. In addition to canola and camelina, YTEN is also engaged with third parties interested in corn, soybean, wheat, and rice. The Trait Factory" is helping to broaden YTEN’s product portfolio. The company has identified three new sectors which could present additional opportunities for for long-term growth; PHA Pharmaceuticals (CBD). We believe the company’s broadening of its core assets as a positive. YTEN expects commercialization could occur within six years, as discussions are ongoing with possible partners." (8/13/2019)

Has Yield10 Bioscience been receiving favorable news coverage?

News headlines about YTEN stock have been trending very negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Yield10 Bioscience earned a news sentiment score of -3.9 on InfoTrie's scale. They also assigned media coverage about the specialty chemicals company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the next several days. View News Stories for Yield10 Bioscience.

Are investors shorting Yield10 Bioscience?

Yield10 Bioscience saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 329,300 shares, a decline of 29.4% from the August 30th total of 466,200 shares. Based on an average daily trading volume, of 165,500 shares, the days-to-cover ratio is presently 2.0 days. Currently, 4.0% of the shares of the company are short sold. View Yield10 Bioscience's Current Options Chain.

Who are some of Yield10 Bioscience's key competitors?

What other stocks do shareholders of Yield10 Bioscience own?

Who are Yield10 Bioscience's key executives?

Yield10 Bioscience's management team includes the folowing people:
  • Dr. Oliver P. Peoples, Co-Founder, Pres, CEO & Director (Age 61)
  • Dr. Anthony J. Sinskey, Co-Founder & Director (Age 79)
  • Dr. Kristi Snell, VP of Research & Chief Science Officer (Age 51)
  • Ms. Lynne H. Brum, VP of Planning & Communications and Sec. (Age 55)
  • Mr. Charles B. Haaser, VP of Fin., Chief Accounting Officer & Treasurer (Age 63)

How do I buy shares of Yield10 Bioscience?

Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Yield10 Bioscience's stock price today?

One share of YTEN stock can currently be purchased for approximately $0.62.

How big of a company is Yield10 Bioscience?

Yield10 Bioscience has a market capitalization of $7.76 million and generates $560,000.00 in revenue each year. The specialty chemicals company earns $-9,170,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Yield10 Bioscience employs 22 workers across the globe.View Additional Information About Yield10 Bioscience.

What is Yield10 Bioscience's official website?

The official website for Yield10 Bioscience is http://www.yield10bio.com/.

How can I contact Yield10 Bioscience?

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at 617-583-1700 or via email at [email protected]


MarketBeat Community Rating for Yield10 Bioscience (NASDAQ YTEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Yield10 Bioscience and other stocks. Vote "Outperform" if you believe YTEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YTEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is a bull market?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel